Home / Resource Library / Encouraging complete responses (CRs) with CDK9 inhibitor AZD4573 in patients (pts) with relapsed/refractory (r/r) peripheral T-cell Lymphoma (PTCL): Early trial analysisEncouraging complete responses (CRs) with CDK9 inhibitor AZD4573 in patients (pts) with relapsed/refractory (r/r) peripheral T-cell Lymphoma (PTCL): Early trial analysis ICML 2023